Projects per year
Personal profile
Education
- MD, College of Medicine, National Defense Medical Center, Taipei, Taiwan.
Experience
- 2022.11- Director, Research Center of Cancer Translational Medicine, Taipei Medical University
- 2022.04- 泰福生技股份有限公司 獨立董事
- 2020.11- Distinguished Investigator and Director of Institute of Biotechnology and Pharmaceutical Research, NHRI
- 2022.11-2024.01 Superintendent, Taipei Cancer Center, Taipei Medical University
- 2020.08 Distinguished Investigator and Attending Physician of National Institute of Cancer Research, NHRI
- 2020.08 Professor Emeritus, National Cheng Kung University
- 2019.02-2020.07 Executive Vice President, National Cheng Kung University
- 2019.02-2020.07 Director of University Center for Bioscience and biotechnology, NCKU
- 2019.01-2020.12 教育部醫學教育會 委員
- 2015.01-2016.12 教育部醫學教育會 委員
- 2014.08-2019.07 Distinguished Professor and Dean, College of Medicine, National Cheng Kung University
- 2013.08-2014.07 Professor and Dean, College of Medicine, National Cheng Kung University
- 2008.09-2018.05 Distinguished Investigator of National Institute of Cancer Research, NHRI
- 2008.01-2013.07 Director of National Institute of Cancer Research, NHRI
- 2007.08~ Attending Physician of Division of hematology/Oncology, NCKUH
- 2007.08-2013.07 Joined Professor, College of Medicine, National Cheng Kung University
- 2006.01-2007.12 Deputy Director of National Institute of Cancer Research, NHRI
- 2004.06-2008 Chairman of Safety and Data Monitoring committee, TCOG
- 2004.04-2008.08 Investigator of NHRI
- 2003.08-2007.07 Adjunct Professor of Internal Medicine, NDMC (部定，教字013198)
- 2003-2005 常務理事，Chinese Oncology Society
- 2001~ Board member of Chinese Oncology Society
- 2000.09-2004.03 Associate investigator of NHRI
- 1999 ~ Board member of Sino-American Cancer Foundation
- 1997-2006 Adjunct Attending physician of Department of Oncology, NTUH
- 1997~ Senior Attending physician of NHRI
- 1997-2001 General Secretary of Chinese Oncology Society
- 1997 Chief of Hematology / Oncology, Cheng-Hsien Medical
Center - 1994-2003.07 Associate Professor of internal medicine, NDMC (部定，副字 21234)
- 1994-1996 Board member of Chinese BMT Society
- 1993-1996 Chief of Medical Oncology, Tri-Service General Hospital, National Defense Medical Center
- 1991-1992 Attending physician of Medical Mission in Republic of Central Africa
- 1989-1991 Visiting Scholar of Yale Medical School, Department of Pharmacology
- 1987-1989 Fellow of Medical Oncology Training Program of Institute of Biomedical Science, Academia Sinica
- 1987-1996 Attending Physician of Hematology / Oncology, Tri-Service General Hospital, NDMC
- 1986-1987 Chief resident of Division of Hematology / Oncology,
Department of Internal Medicine, TSGH, NDMC - 1982-1986 Resident of Department of Medicine, TSGH, NDMC
- 1981-1982 Internship training, Tri-Service General Hospital
Research Interests
- Development of anticancer drugs
- Study the mechanisms of anticancer drug resistance
Fingerprint
Dive into the research topics where Jang-Yang Chang is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Investigation of the Role of Cathepsin S in Regulation of Lysosome and Its Clinical Relevance in Head and Neck Cancer( I )
Chang, J.-Y. (PI)
8/1/24 → 7/31/25
Project: A - Government Institution › b - National Science and Technology Council
-
Elucidating Lysosomal Cysteine Protease Cathepsin S in Tumor Immunity of Head and Neck Cancer: Focusing on Its Regulatory Roles in Il-7 and Potential Immunomodulatory Mechanisms( III )
Chang, J.-Y. (PI)
8/1/23 → 7/31/24
Project: A - Government Institution › b - National Science and Technology Council
-
112年高教深耕-癌症轉譯研究中心計畫
Chang, J.-Y. (PI)
1/1/23 → 12/31/23
Project: B - Project of TMU › h - Higher Education Sprout Project
-
Investigation the Role of Cathepsin S in Oxaliplatin-Induced Neuropathy: Potential Biomarker for Prediction and Prevention of Peripheral Neuropathy( III )
Chang, J.-Y. (PI)
8/1/22 → 7/31/23
Project: A - Government Institution › b - National Science and Technology Council
-
Elucidating Lysosomal Cysteine Protease Cathepsin S in Tumor Immunity of Head and Neck Cancer: Focusing on Its Regulatory Roles in Il-7 and Potential Immunomodulatory Mechanisms( II )
Chang, J.-Y. (PI)
8/1/22 → 7/31/23
Project: A - Government Institution › b - National Science and Technology Council
-
Oral Cancer-Derived miR-762 Suppresses T-Cell Infiltration and Activation by Horizontal Inhibition of CXCR3 Expression
Peng, H. Y., Chang, C. W., Wu, P. H., Li, L. J., Lin, Y. L., Hsiao, M., Chang, J. Y., Chang, P. M. H., Lee, H. L. & Chang, W. M., Feb 2025, In: International journal of molecular sciences. 26, 3, 1077.Research output: Contribution to journal › Article › peer-review
Open Access -
The miR-876-5p/SOCS4/STAT3 pathway induced the expression of PD-L1 and suppressed antitumor immune responses
Peng, H. Y., Huang, Y. L., Wu, P. H., Li, L. J., Peng, B. Y., Wu, C. Y., Lin, Y. L., Hsiao, M., Chang, J. Y., Mu-Hsin Chang, P., Lee, H. L. & Chang, W. M., Dec 2025, In: Cancer Cell International. 25, 1, 114.Research output: Contribution to journal › Article › peer-review
-
Correction: The Synergistic Inhibition of Coronavirus Replication and Induced Cytokine Production by Ciclesonide and the Tylophorine-Based Compound Dbq33b (Pharmaceutics, (2022), 14, (1511), 10.3390/pharmaceutics14071511)
Lee, Y. Z., Hsu, H. Y., Yang, C. W., Lin, Y. L., Chang, S. Y., Yang, R. B., Liang, J. J., Chao, T. L., Liao, C. C., Kao, H. C., Chang, J. Y., Sytwu, H. K., Chen, C. T. & Lee, S. J., Feb 2023, In: Pharmaceutics. 15, 2, 342.Research output: Contribution to journal › Comment/debate › peer-review
Open Access -
How to deal with frenemy NRF2: Targeting NRF2 for chemoprevention and cancer therapy
Tang, Y. C., Chuang, Y. J., Chang, H. H., Juang, S. H., Yen, G. C., Chang, J. Y. & Kuo, C. C., 2023, In: Journal of Food and Drug Analysis. 31, 3, p. 387-407 21 p., 2.Research output: Contribution to journal › Review article › peer-review
Open Access2 Citations (Scopus) -
Lysosomal-targeted doxorubicin delivery using RBC-derived vesicles to overcome drug-resistant cancer through mitochondrial-dependent cell death
Lin, C. P., Wu, S. H., Lin, T. Y., Chu, C. H., Lo, L. W., Kuo, C. C., Chang, J. Y., Hsu, S. C., Ko, B. S., Yao, M., Hsiao, J. K., Wang, S. W. & Huang, D. M., Nov 2023, In: Pharmacological Research. 197, 106945.Research output: Contribution to journal › Article › peer-review
Open Access3 Citations (Scopus)
Datasets
-
Novel microtubule inhibitor MPT0B098 inhibits hypoxia-induced epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma
Tsai, I.-T. (Contributor), Kuo, C.-C. (Contributor), Liou, J.-P. (Creator) & Chang, J.-Y. (Contributor), Figshare, 2018
DOI: 10.6084/m9.figshare.c.4052207.v1, https://figshare.com/collections/Novel_microtubule_inhibitor_MPT0B098_inhibits_hypoxia-induced_epithelial-to-mesenchymal_transition_in_head_and_neck_squamous_cell_carcinoma/4052207/1
Dataset